226 related articles for article (PubMed ID: 15128765)
1. CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction.
Garbi N; Arnold B; Gordon S; Hämmerling GJ; Ganss R
J Immunol; 2004 May; 172(10):5861-9. PubMed ID: 15128765
[TBL] [Abstract][Full Text] [Related]
2. Targeted liposomal delivery of TLR9 ligands activates spontaneous antitumor immunity in an autochthonous cancer model.
Hamzah J; Altin JG; Herringson T; Parish CR; Hämmerling GJ; O'Donoghue H; Ganss R
J Immunol; 2009 Jul; 183(2):1091-8. PubMed ID: 19561111
[TBL] [Abstract][Full Text] [Related]
3. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity.
Davila E; Celis E
J Immunol; 2000 Jul; 165(1):539-47. PubMed ID: 10861094
[TBL] [Abstract][Full Text] [Related]
4. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
Davila E; Kennedy R; Celis E
Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
[TBL] [Abstract][Full Text] [Related]
5. APC stimulated by CpG oligodeoxynucleotide enhance activation of MHC class I-restricted T cells.
Warren TL; Bhatia SK; Acosta AM; Dahle CE; Ratliff TL; Krieg AM; Weiner GJ
J Immunol; 2000 Dec; 165(11):6244-51. PubMed ID: 11086059
[TBL] [Abstract][Full Text] [Related]
6. CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide.
Miconnet I; Koenig S; Speiser D; Krieg A; Guillaume P; Cerottini JC; Romero P
J Immunol; 2002 Feb; 168(3):1212-8. PubMed ID: 11801657
[TBL] [Abstract][Full Text] [Related]
7. Antigenic epitopes fused to cationic peptide bound to oligonucleotides facilitate Toll-like receptor 9-dependent, but CD4+ T cell help-independent, priming of CD8+ T cells.
Schirmbeck R; Riedl P; Zurbriggen R; Akira S; Reimann J
J Immunol; 2003 Nov; 171(10):5198-207. PubMed ID: 14607920
[TBL] [Abstract][Full Text] [Related]
8. Development of a novel Ag-specific immunotherapy using CpG oligodeoxynucleotides in a new, unique mouse cutaneous eosinophilic inflammation model.
Kootiratrakarn T; Fujimura T; Sano K; Okuyama R; Aiba S; Tagami H; Terui T
Eur J Immunol; 2005 Nov; 35(11):3277-86. PubMed ID: 16245360
[TBL] [Abstract][Full Text] [Related]
9. Increase in tumor size following intratumoral injection of immunostimulatory CpG-containing oligonucleotides in a rat glioma model.
Ginzkey C; Eicker SO; Marget M; Krause J; Brecht S; Westphal M; Hugo HH; Mehdorn HM; Steinmann J; Hamel W
Cancer Immunol Immunother; 2010 Apr; 59(4):541-51. PubMed ID: 19798500
[TBL] [Abstract][Full Text] [Related]
10. Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN.
de Jong S; Chikh G; Sekirov L; Raney S; Semple S; Klimuk S; Yuan N; Hope M; Cullis P; Tam Y
Cancer Immunol Immunother; 2007 Aug; 56(8):1251-64. PubMed ID: 17242927
[TBL] [Abstract][Full Text] [Related]
11. Tumor microenvironment can restrict the effectiveness of activated antitumor lymphocytes.
Ganss R; Hanahan D
Cancer Res; 1998 Oct; 58(20):4673-81. PubMed ID: 9788621
[TBL] [Abstract][Full Text] [Related]
12. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract.
Gallichan WS; Woolstencroft RN; Guarasci T; McCluskie MJ; Davis HL; Rosenthal KL
J Immunol; 2001 Mar; 166(5):3451-7. PubMed ID: 11207303
[TBL] [Abstract][Full Text] [Related]
13. Priming MHC-I-restricted cytotoxic T lymphocyte responses to exogenous hepatitis B surface antigen is CD4+ T cell dependent.
Wild J; Grusby MJ; Schirmbeck R; Reimann J
J Immunol; 1999 Aug; 163(4):1880-7. PubMed ID: 10438922
[TBL] [Abstract][Full Text] [Related]
14. Enhanced tumor-specific long-term immunity of hemagglutinating [correction of hemaggluttinating] virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides.
Hiraoka K; Yamamoto S; Otsuru S; Nakai S; Tamai K; Morishita R; Ogihara T; Kaneda Y
J Immunol; 2004 Oct; 173(7):4297-307. PubMed ID: 15383558
[TBL] [Abstract][Full Text] [Related]
15. NK- and CD8(+) T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides.
Kawarada Y; Ganss R; Garbi N; Sacher T; Arnold B; Hämmerling GJ
J Immunol; 2001 Nov; 167(9):5247-53. PubMed ID: 11673539
[TBL] [Abstract][Full Text] [Related]
16. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen.
Davis HL; Weeratna R; Waldschmidt TJ; Tygrett L; Schorr J; Krieg AM
J Immunol; 1998 Jan; 160(2):870-6. PubMed ID: 9551923
[TBL] [Abstract][Full Text] [Related]
17. G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice.
Gekeler V; Gimmnich P; Hofmann HP; Grebe C; Römmele M; Leja A; Baudler M; Benimetskaya L; Gonser B; Pieles U; Maier T; Wagner T; Sanders K; Beck JF; Hanauer G; Stein CA
Oligonucleotides; 2006; 16(1):83-93. PubMed ID: 16584297
[TBL] [Abstract][Full Text] [Related]
18. In vivo impact of CpG1826 oligodeoxynucleotide on CD8 T cell primary responses and survival.
Beloeil L; Tomkowiak M; Angelov G; Walzer T; Dubois P; Marvel J
J Immunol; 2003 Sep; 171(6):2995-3002. PubMed ID: 12960324
[TBL] [Abstract][Full Text] [Related]
19. Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model.
Heckelsmiller K; Rall K; Beck S; Schlamp A; Seiderer J; Jahrsdörfer B; Krug A; Rothenfusser S; Endres S; Hartmann G
J Immunol; 2002 Oct; 169(7):3892-9. PubMed ID: 12244187
[TBL] [Abstract][Full Text] [Related]
20. Accumulation of CD8+ T cells in advanced-stage tumors and delay of disease progression following secondary immunization against an immunorecessive epitope.
Ryan CM; Schell TD
J Immunol; 2006 Jul; 177(1):255-67. PubMed ID: 16785521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]